Advanced Urothelial Carcinoma
Advanced Urothelial Carcinoma
Advertisement
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | October 1, 2024
At ESMO Congress 2024, Drs. Petros Grivas, Bernadett Szabados, and Karine Tawagi discuss ctDNA biomarkers.
View More
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | September 23, 2024
Dr. Koshkin highlights phase 2 data on futibatinib plus pembrolizumab for advanced urothelial carcinoma.
Amanda Nizam, MDAdvanced Urothelial Carcinoma | September 23, 2024
Drs. Tawagi, Nizam encourage earlier monitoring and intervention to mitigate EV-induced neuropathy in certain patients.
Jordana JampelAdvanced Renal Cell Carcinoma | September 30, 2024
Better quality of life and higher optimism showed to alter the perception people with metastatic disease have about cure.
Matthew Galsky, MDAdvanced Urothelial Carcinoma | September 18, 2024
Dr. Galsky discusses the value of HER2 status and the promising 75% ORR from the phase 2 trial.
Zachary BessetteAdvanced Urothelial Carcinoma | September 13, 2024
EV/pembro may offer first-line PFS and OS benefit in patients with la/mUC, regardless of Nectin-4 expression.
Zachary BessetteAdvanced Urothelial Carcinoma | September 12, 2024
A phase 2 study highlights the “encouraging” antitumor activity from futibatinib plus pembrolizumab for patients with ...
Brandon TwyfordAdvanced Urothelial Carcinoma | September 12, 2024
Disitamab vedotin plus pembrolizumab shows promising efficacy, manageable safety in HER2+ aUC, with a 61.1% response rate.
Jordana JampelAdvanced Urothelial Carcinoma | September 10, 2024
In patients with pretreated UC, BL-B01D1 demonstrated manageable safety with encouraging antitumor activity.
Jordana JampelAdvanced Urothelial Carcinoma | September 10, 2024
Enfortumab vedotin plus pembrolizumab showed consistent PFS and OS benefit across all subgroups.
Emily MenendezAdvanced Urothelial Carcinoma | September 5, 2024
Cohort 2 of TROPHY-U-01 showed that sacituzumab govitecan monotherapy can benefit cisplatin-ineligible patients.
Guru P. Sonpavde, MDAdvanced Urothelial Carcinoma | August 12, 2024
Dr. Sonpavde shares his thoughts on first-line therapy for aUC, including trials like CheckMate 274, AMBASSADOR, and NIAGRA.
Enrique Grande, MD, PhD, MScAdvanced Urothelial Carcinoma | July 30, 2024
Drs. Grande, Nizam continue their conversation on EVITA, including the personalization of treatment to predict toxicity.
Enrique Grande, MD, PhD, MScAdvanced Urothelial Carcinoma | July 30, 2024
Drs. Grande and Nizam discuss the development of criteria for identifying mUC patients ineligible for EV/pembro.
Shilpa Gupta, MDAdvanced Urothelial Carcinoma | July 16, 2024
Drs. Gupta and Nizam discuss the findings from the patient-reported outcomes in the EV-302 trial for urothelial carcinoma.
Katy MarshallAdvanced Urothelial Carcinoma | July 8, 2024
The recorded ORR was 53.5%, and the disease control rate was 74.1%.
Niklas Klümper, MDAdvanced Urothelial Carcinoma | June 21, 2024
Dr. Klümper highlights an analysis of NECTIN4 amplification as a biomarker for predicting response to EV in mUC treatment.
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | June 12, 2024
Dr. Grivas offers long-term outcomes from the JAVELIN Bladder 100 study pertaining to specific patient populations.
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | June 12, 2024
Dr. Grivas provides an update on relevant clinical trial updates and data readouts pertaining to urothelial carcinoma.
Michiel van der Heijden, MD, PhDAdvanced Urothelial Carcinoma | June 6, 2024
Drs. van der Heijden and Nizam weigh the EV-302 subanalyses of the cisplatin-eligible, -ineligible populations.
Advertisement
Advertisement
Advertisement